1921
Volume 99, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The cost-effectiveness of the standard of care for snakebite treatment, antivenom, and supportive care has been established in various settings. In this study, based on data from South Indian private health-care providers, we address an additional question: “For what cost and effectiveness values would adding adjunct-based treatment strategies to the standard of care for venomous snakebites be cost-effective?” We modeled the cost and performance of potential interventions (e.g., pharmacologic or preventive) used adjunctively with antivenom and supportive care for the treatment of snakebite. Because these potential interventions are theoretical, we used a threshold cost-effectiveness approach to explore this forward-looking concept. We examined economic parameters at which these interventions could be cost-effective or even cost saving. A threshold analysis was used to examine the addition of new interventions to the standard of care. Incremental cost-effectiveness ratios were used to compare treatment strategies. One-way, scenario, and probabilistic sensitivity analyses were conducted to analyze parameter uncertainty and define cost and effectiveness thresholds. Our results suggest that even a 3% reduction in severe cases due to an adjunct strategy is likely to reduce the cost of overall treatment and have the greatest impact on cost-effectiveness. In this model, for example, an investment of $10 of intervention that reduces the incidence of severe cases by 3%, even without changing antivenom usage patterns, creates cost savings of $75 per individual. These findings illustrate the striking degree to which an adjunct intervention could improve patient outcomes and be cost-effective or even cost saving.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0922
2018-08-02
2018-08-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/2/tpmd170922.html?itemId=/content/journals/10.4269/ajtmh.17-0922&mimeType=html&fmt=ahah

References

  1. Lozano R, 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 20952128.
  2. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA, , 2017. Snakebite envenoming. Nat Rev Dis Primers 3: 17063.
  3. Vaiyapuri S, 2013. Snakebite and its socio-economic impact on the rural population of Tamil Nadu, India. PLoS One 8: 1013.
  4. Kawabata K, Xu K, Carrin G, , 2002. Preventing impoverishment through protection against catastrophic health expenditure. Bull World Health Organ 80: 612.
  5. Chippaux JP, , 1998. Snake-bites: appraisal of the global situation. Bull World Health Organ 76: 515524.
  6. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ, , 2008. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5: e218.
  7. Mohapatra B, Warrell DA, Suraweera W, Bhatia P, Dhingra N, Jotkar RM, Rodriguez PS, Mishra K, Whitaker R, Jha P, Million Death Study Collaborators; , 2011. Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl Trop Dis 5: e1018.
  8. Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG, , 2009. Snake envenoming: a disease of poverty. PLoS Negl Trop Dis 3: e569.
  9. Looareesuwan S, Viravan C, Warrell DA, , 1988. Factors contributing to fatal snake bite in the rural tropics: analysis of 46 cases in Thailand. Trans R Soc Trop Med Hyg 82: 930934.
  10. Sharma SK, Chappuis FF, Jha N, Bovier PA, Loutan L, Koirala S, , 2004. Impact of snake bites and determinants of fatal outcomes in southeastern Nepal. Am J Trop Med Hyg 71: 234238.
  11. Gutiérrez JM, Theakston RDG, Warrell DA, , 2006. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med 3: e150.
  12. WHO, 2017. World Health Organization—Neglected Tropical Diseases. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/neglected_diseases/diseases/en/. Accessed November 2, 2017.
  13. Brown NI, , 2012. Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context. PLoS Negl Trop Dis 6: e1670.
  14. Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez M, Lohse B, , 2016. From fangs to pharmacology: the future of snakebite envenoming therapy. Curr Pharm Des 22: 52705293.
  15. Carvalho BM, 2013. Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules. Biomed Res Int 2013: 153045.
  16. Olver CS, Nielsen VG, , 2017. Iron protects porcine plasma coagulation kinetics from degradation by Crotalus atrox venom. Biometals 30: 677683.
  17. Chen Y-J, Tsai C-Y, Hu W-P, Chang L-S, , 2016. DNA aptamers against Taiwan banded krait α-bungarotoxin recognize Taiwan cobra cardiotoxins. Toxins (Basel) 8: 66.
  18. Lewin M, Samuel S, Merkel J, Bickler P, , 2016. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins (Basel) 8: pii: E248.
  19. Laustsen AH, , 2016. Snakebites: costing recombinant antivenoms. Nature 538: 41.
  20. Açikalin A, Gökel Y, Kuvandik G, Duru M, Köseoğlu Z, Satar S, , 2008. The efficacy of low-dose antivenom therapy on morbidity and mortality in snakebite cases. Am J Emerg Med 26: 402407.
  21. Brown N, Landon J, , 2010. Antivenom: the most cost-effective treatment in the world? Toxicon 55: 14051407.
  22. Vargas M, 2011. Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea. PLoS Negl Trop Dis 5: e1144.
  23. Das RR, Sankar J, Dev N, , 2015. High-dose versus low-dose antivenom in the treatment of poisonous snake bites: a systematic review. Indian J Crit Care Med 19: 340349.
  24. Chippaux J-P, Akaffou MH, Allali BK, Dosso M, Massougbodji A, Barraviera B, , 2016. The 6th international conference on envenomation by snakebites and scorpion stings in Africa: a crucial step for the management of envenomation. J Venom Anim Toxins Incl Trop Dis 22: 11.
  25. Darryl W, Sartorius B, Hift R, , 2016. Estimating the burden of snakebite on public hospitals in KwaZulu Natal, South Africa. Wilderness Environ Med 27: 5361.
  26. Price JA, , 2015. Microplate fluorescence protease assays test the inhibition of select North American snake venoms’ activities with an anti-proteinase library. Toxicon 103: 145154.
  27. Fernandes CAH, Cardoso FF, Cavalcante WGL, Soares AM, Dal-Pai M, Gallacci M, Fontes MRM, , 2015. Structural basis for the inhibition of a phospholipase A2-like toxin by caffeic and aristolochic acids. PLoS One 10: e0133370.
  28. Howes J-M, Theakston RDG, Laing GD, , 2007. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. Toxicon 49: 734739.
  29. Arias AS, Rucavado A, Gutiérrez J-M, , 2017. Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom. Toxicon 132: 4049.
  30. Habib AG, Lamorde M, Dalhat MM, Habib ZG, Kuznik A, , 2015. Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria. PLoS Negl Trop Dis 9: e3381.
  31. Hamza M, Idris MA, Maiyaki MB, Lamorde M, Chippaux J-P, Warrell DA, Kuznik A, Habib AG, , 2016. Cost-effectiveness of antivenoms for snakebite envenoming in 16 countries in West Africa. PLoS Negl Trop Dis 10: e0004568.
  32. Ministry of Health and Family Welfare, Government of India, 2015. National Health Policy 2015, Draft. Guwahati, Assam, India: Ministry Of Health and Family Welfare, Government of India.
  33. Bustreo F, Harding A, Axelsson H, , 2003. Can developing countries achieve adequate improvements in child health outcomes without engaging the private sector? Bull World Health Organ 81: 886895.
  34. Bloomberg, 2014. Foreign Exchange Rates & World Currencies—Bloomberg. New York, NY: Bloomberg Inc.
  35. Chaudhari TS, Patil TB, Paithankar MM, Gulhane RV, Patil MB, , 2014. Predictors of mortality in patients of poisonous snake bite: experience from a tertiary care hospital in central India. Int J Crit Illn Inj Sci 4: 101107.
  36. Majumder D, Sinha A, Bhattacharya SK, Ram R, Dasgupta U, Ram A, , 2014. Epidemiological profile of snake bite in South 24 Parganas district of West Bengal with focus on underreporting of snake bite deaths. Indian J Public Health 58: 1721.
  37. Sankar J, Nabeel R, Sankar MJ, Priyambada L, Mahadevan S, , 2013. Factors affecting outcome in children with snake envenomation: a prospective observational study. Arch Dis Child 98: 596601.
  38. Gautam P, Sharma N, Sharma M, Choudhary S, , 2014. Clinical and demographic profile of snake envenomation in Himachal Pradesh, India. Indian Pediatr 51: 934935.
  39. Ariaratnam CA, Thuraisingam V, Kularatne SAM, Sheriff MHR, Theakston RDG, de Silva A, Warrell DA, , 2008. Frequent and potentially fatal envenoming by hump-nosed pit vipers (Hypnale hypnale and H. nepa) in Sri Lanka: lack of effective antivenom. Trans R Soc Trop Med Hyg 102: 11201126.
  40. Ahmed SM, Nadeem A, Islam MS, Agarwal S, Singh L, , 2012. Retrospective analysis of snake victims in northern India admitted in a tertiary level institute. J Anaesthesiol Clin Pharmacol 28: 4550.
  41. WHO, 2004. Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva, Switzerland: WHO. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed November 2, 2017.
  42. Global Burden of Disease Study, 2010. (GBD 2010) Disability Weights | GHDx. Available at: http://ghdx.healthdata.org/record/global-burden-disease-study-2010-gbd-2010-disability-weights. Accessed November 2, 2017.
  43. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, ISPOR-SMDM Modeling Good Research Practices Task Force; , 2012. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value Health 15: 835842.
  44. World Bank, 2015. GDP Per Capita, India (Current US$). Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=IN&name_desc=false. Accessed April 14, 2018.
  45. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S, , 2015. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ 93: 118124.
  46. Sekhri Feachem N, Afshar A, Pruett C, Avanceña ALV, , 2017. Mapping healthcare systems: a policy relevant analytic tool. Int Health 9: 252262.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0922
Loading
/content/journals/10.4269/ajtmh.17-0922
Loading

Data & Media loading...

Supplementary Data

Supplemental Tables

  • Received : 27 Nov 2017
  • Accepted : 15 Apr 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error